• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Billions With Nutrition Deficiency!?
Almost no one gets enough selenium. Officially, at least a billion — with a B — people have a selenium deficiency.1 But I suspect the numbers are much higher than that. You can’t get enough selenium from food alone anymore. That’s true even if you eat a healthy, varied diet. And you can thank Big Agra for that. With their harsh pesticides, synthetic fertilizers, and single-crop strategy, these massive farms have stripped the nutrients out of the soil. No nutrients in the soil mean no nutrients in the food. All of this makes it difficult — if not impossible — to get even some of the daily selenium you need to ...
Source: Al Sears, MD Natural Remedies - May 15, 2023 Category: Complementary Medicine Authors: Jacob Tags: Anti-Aging Nutrition Source Type: news

High-fructose diet hampers recovery from traumatic brain injury
A diet high in processed fructose sabotages rats’ brains’ ability to heal after head trauma, UCLA neuroscientists report. Revealing a link between nutrition and brain health, the finding offers implications for the 5.3 million Americans living with a traumatic brain injury, or TBI. According to the Centers for Disease Control and Prevention, an estimated 1.7 million people suffer a TBI each year, resulting in 52,000 annual deaths “Americans consume most of their fructose from processed foods sweetened with high-fructose corn syrup,” said Fernando Gomez-Pinilla, a professor of neurosurgery and integrative biology an...
Source: UCLA Newsroom: Health Sciences - October 2, 2015 Category: Universities & Medical Training Source Type: news

Reflections on the Future of Medicine
Recently, I traveled through China. I climbed mountains, hiked through forests, crossed deep valleys. I visited cities of every size. I floated across lakes and traveled beautiful shorelines churning with life. As a man of a certain age, I began to compare the permanence of the timeless landscape with the evanescence of my own existence. Yet, as a scientist, I knew these reflections were flawed. Scientists are trained to think in terms of aeons, millenia, and lifetimes. Consider the paradox. Is it the solid mountain or fragile the forest that is permanent? Is it the massive shoreline cliffs or the teeming shore life that...
Source: Science - The Huffington Post - January 9, 2017 Category: Science Source Type: news

Sex Difference of Radiation Response in Occupational and Accidental Exposure
Conclusion and Outlook This review summarizes the data from major human studies on the health risks of radiation exposure and shows that sex can potentially influence the prolonged response to radiation exposure (Figure 1 and Tables 1, 2). These data suggest that long-term radiosensitivity in females is higher than that in males who receive a comparable dose of radiation. Our analysis of the literature agrees with the conclusions of the recent report on the Biological effects of ionizing radiation (BEIR VII) published in 2006 by the National Academy of Sciences (NAS), United States (National Research Council, 2006). The B...
Source: Frontiers in Genetics - May 2, 2019 Category: Genetics & Stem Cells Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Q & A: Dr. Thomas Rando on preventing age-related diseases and turning discoveries into cures
For Dr. Thomas Rando, the path to becoming a physician-scientist began with something that hedidn ’t learn in high school biology.After one class that touched on the connections between neurons and muscle fibers, Rando took it upon to himself to find all the information he could about how cells communicate through electrical signals.Soon, he began pursuing that interest at Harvard University, where he completed his undergraduate work, a doctorate in cell and developmental biology and his medical degree.Rando joined the neurology faculty at the Stanford University School of Medicine in 1995.There, he founded a clinic to t...
Source: UCLA Newsroom: Health Sciences - December 10, 2021 Category: Universities & Medical Training Source Type: news

Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news